Clinical Trials Browser

Neoplasm, Residual × obinutuzumab × 90 days × Clear all

NCT05929222 2026-06-01

FIL_GAZEBO

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Neoplasm, Residual

NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

Phase 2 Active not recruiting

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell